Cargando…
Joint action of miR‐126 and MAPK/PI3K inhibitors against metastatic melanoma
Emerging data support the rationale of combined therapies in advanced melanoma. Specifically, the combined use of drugs with different mechanisms of action can reduce the probability of selecting resistant clones. To identify agents active against melanoma cells, we screened a library of 349 anti‐ca...
Autores principales: | Pedini, Francesca, De Luca, Gabriele, Felicetti, Federica, Puglisi, Rossella, Boe, Alessandra, Arasi, Maria Beatrice, Fratini, Federica, Mattia, Gianfranco, Spada, Massimo, Caporali, Simona, Biffoni, Mauro, Giuliani, Alessandro, Carè, Alessandra, Felli, Nadia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717748/ https://www.ncbi.nlm.nih.gov/pubmed/31115969 http://dx.doi.org/10.1002/1878-0261.12506 |
Ejemplares similares
-
miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma
por: Felli, Nadia, et al.
Publicado: (2013) -
AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression
por: Felli, N, et al.
Publicado: (2016) -
Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis
por: Arasi, Maria Beatrice, et al.
Publicado: (2020) -
Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma
por: Felicetti, Federica, et al.
Publicado: (2016) -
SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma
por: Puglisi, Rossella, et al.
Publicado: (2018)